DNA methyltransferase inhibitors in hematological malignancies and solid tumors

Documenti analoghi

• Antigen escape in CAR ‐T therapy: A tumor microenvironment perspective from hematological to solid tumors
  di: Shuai Wang, et al.
  Pubblicazione: (2025)
• Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
  di: Maike Janssen, et al.
  Pubblicazione: (2024)
• Changes in mortality associated with different hematologic malignancies during the pandemic in the United States
  di: Ugo Fedeli, et al.
  Pubblicazione: (2024)
• Exclusion of patients with renal impairment from phase 3 randomized controlled trials in hematologic malignancies
  di: Danuta Kłosowska, et al.
  Pubblicazione: (2025)
• Residential exposure to solar ultraviolet radiation and risk of childhood hematological malignancies in Switzerland: A census‐based cohort study
  di: Astrid Coste, et al.
  Pubblicazione: (2024)